Literature DB >> 35445175

Application of Personal Health Record in Enhancing the Quality of Life in Patients With Breast Cancer Who Received Adjuvant Hormonal Therapy.

Fuka Takada1, Hiromi Okuyama1,2,3, Seigo Nakamura3, Ken-Ichi Fujita1.   

Abstract

Objective: Recently, personal health records (PHR) have become a communication tool between patients and medical professionals. PHR applications (PHR app) can be installed on smartphones to record patient-reported outcomes (PROs). This study prospectively examined whether patients with breast cancer could record PROs, including subjective and objective symptoms, on PHR app. Materials and
Methods: Patients who received adjuvant hormonal therapy were enrolled. The patients were asked to collect PROs related to physical conditions, symptoms, and medications on their PHR app from the beginning of therapy for one month. Quality of life (QoL) was evaluated before treatment initiation and one month after. Patients completed a questionnaire of their opinions concerning the PHR app after use.
Results: Fourteen patients were enrolled between October and December 2020. All patients could use the PHR app during the study period without any negative effects on QoL. Eleven (79%) patients fully recorded their PROs on the app. Typical side effects induced by hormonal therapy to reduce the QoL were observed (hot flash in two patients, 14.3%). The questionnaire revealed that approximately 70% wanted to use the PHR app in the future to communicate with medical staff and to report adverse events. Specifically, 90% of patients who experienced difficulty communicating with medical staff wanted to use the PHR app. Some patients wanted to utilize the PHR app to set reminders to take medications.
Conclusion: The PHR app can be applied as a communication tool between patients taking adjuvant hormonal therapy and medical professionals. ©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.

Entities:  

Keywords:  Breast cancer; adverse event; hormonal therapy; patient reported outcome; personal health records; quality of life

Year:  2022        PMID: 35445175      PMCID: PMC8987863          DOI: 10.4274/ejbh.galenos.2022.2021-12-2

Source DB:  PubMed          Journal:  Eur J Breast Health


  18 in total

1.  Symptoms and Symptom Attribution Among Women on Endocrine Therapy for Breast Cancer.

Authors:  Shoshana M Rosenberg; Annette L Stanton; Keith J Petrie; Ann H Partridge
Journal:  Oncologist       Date:  2015-05-01

2.  Perspectives of postmenopausal breast cancer survivors on adjuvant endocrine therapy-related symptoms.

Authors:  G J van Londen; Heidi S Donovan; Ellen B Beckjord; Alexandra L Cardy; Dana H Bovbjerg; Nancy E Davidson; Jennifer Q Morse; Galen E Switzer; Irma M Verdonck-de Leeuw; Mary Amanda Dew
Journal:  Oncol Nurs Forum       Date:  2014-11-01       Impact factor: 2.172

3.  Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

Authors:  M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 4.  What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials.

Authors:  Grigorios Kotronoulas; Nora Kearney; Roma Maguire; Alison Harrow; David Di Domenico; Suzanne Croy; Stephen MacGillivray
Journal:  J Clin Oncol       Date:  2014-04-07       Impact factor: 44.544

5.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer.

Authors:  Dawn L Hershman; Theresa Shao; Lawrence H Kushi; Donna Buono; Wei Yann Tsai; Louis Fehrenbacher; Marilyn Kwan; Scarlett Lin Gomez; Alfred I Neugut
Journal:  Breast Cancer Res Treat       Date:  2010-08-28       Impact factor: 4.872

6.  Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer.

Authors:  Erin J Aiello Bowles; Denise M Boudreau; Jessica Chubak; Onchee Yu; Monica Fujii; Janet Chestnut; Diana S M Buist
Journal:  J Oncol Pract       Date:  2012-07-17       Impact factor: 3.840

7.  Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.

Authors:  Ethan Basch; Allison M Deal; Mark G Kris; Howard I Scher; Clifford A Hudis; Paul Sabbatini; Lauren Rogak; Antonia V Bennett; Amylou C Dueck; Thomas M Atkinson; Joanne F Chou; Dorothy Dulko; Laura Sit; Allison Barz; Paul Novotny; Michael Fruscione; Jeff A Sloan; Deborah Schrag
Journal:  J Clin Oncol       Date:  2015-12-07       Impact factor: 44.544

Review 8.  Measuring quality of life in patients with breast cancer: a systematic review of reliable and valid instruments available in Japan.

Authors:  Takahiro Okamoto; Kojiro Shimozuma; Noriyuki Katsumata; Michiko Koike; Akinori Hisashige; Katsuhiro Tanaka; Shozo Ohsumi; Mitsue Saito; Naoto Shikama; Michihide Mitsumori; Chikako Yamauchi; Takanori Watanabe
Journal:  Breast Cancer       Date:  2003       Impact factor: 4.239

9.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316

10.  Integrated personal health records: transformative tools for consumer-centric care.

Authors:  Don Detmer; Meryl Bloomrosen; Brian Raymond; Paul Tang
Journal:  BMC Med Inform Decis Mak       Date:  2008-10-06       Impact factor: 2.796

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.